The Application of Immune Checkpoint Inhibitors Combined with Chemotherapy in Tumor Immunotherapy

3,286
Total downloads
14k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 20 May 2025

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

Yang Zhang
Yang Yang
Yuanyuan Zeng
Qiuxia Qu
Dan Shen
Chuanyong Mu
Wei Lei
Meiqin Su
Jingyu Mao
3 more
Jian-an Huang

doi 10.3389/fimmu.2025.1553042

362 views

CASE REPORT

Published on 01 May 2025

Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report

Juan Lang
Qianqian Liu
Rong Ji
Miao Qiu
Siben Wang
Qingmeng Liu
Dapeng Li
Ping Chen
Zhongkui Xiong

doi 10.3389/fimmu.2025.1573202

983 views

ORIGINAL RESEARCH

Published on 28 Apr 2025

The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study

Bicheng Zhang
Yuxiao Song
Qian Min
Weiting Cheng
Jun Wang
Yang Fu
Jiaxin Yin

doi 10.3389/fimmu.2025.1579420

694 views

ORIGINAL RESEARCH

Published on 14 Apr 2025

Comparison of immunotherapy based total neoadjuvant therapy or standard neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional retrospective study

Wen Zhao
Wenxing Gao
Jitao Du
Dingchang Li
Xianqiang Liu
Zhengyao Chang
Peng Chen
Xu Sun
Yingjie Zhao
2 more
Guanglong Dong

doi 10.3389/fimmu.2025.1513716

742 views

REVIEW

Published on 08 Apr 2025

Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis

Yunnan Zhang
Wenxing Peng
Wei Yang
Wenzhou Zhang
Yannan Fan

doi 10.3389/fimmu.2025.1500954

1,147 views

ORIGINAL RESEARCH

Published on 27 Mar 2025

Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis

Yubingxue Liu
Jianlin Long
Huan Deng
Wen Chen

doi 10.3389/fimmu.2025.1548665

1,514 views

ORIGINAL RESEARCH

Accepted on 17 Mar 2025

Efficacy and safety of Geptanolimab in previously treated PD-L1-Positive recurrent or metastatic cervical cancer: a multi-center openlabel, single-arm, phase Ⅱ study

Jusheng An
Mei Feng
Ke-Qiang Zhang
Jianqing Zhu
Aiqin He
Xiumin Li
Jin Peng
Xinwen Wang
Hongping Zhang
22 more
Lingying Wu

doi 10.3389/fonc.2025.1528276

141 views

CASE REPORT

Published on 10 Mar 2025

Case Report: Metastatic succinate dehydrogenase–deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor

Arthur Claessens
Jérôme Edouard Plaza
Jean-Yves Blay

doi 10.3389/fonc.2025.1549232

1,067 views
1 citation

ORIGINAL RESEARCH

Published on 14 Feb 2025

Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer

Zeyu Liu
Aina Liu
Ming Li
Jinyu Xiang
Guohua Yu
Ping Sun

doi 10.3389/fimmu.2025.1545304

858 views

BRIEF RESEARCH REPORT

Published on 31 Jan 2025

The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

Jifeng Feng
Liang Wang
Xun Yang
Qixun Chen

doi 10.3389/fimmu.2025.1535507

896 views
1 citation

CASE REPORT

Published on 23 Jan 2025

Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review

Xiaojing Liang
Guoqing Xu
Jisong Zhang
Li Xu
Liangliang Dong
Xiaoyue Wang
Weidong Han
Enguo Chen

doi 10.3389/fimmu.2025.1523316

963 views
1 citation

CASE REPORT

Published on 24 Dec 2024

Case report: Aggressive NSCLC with partial BRG-1 deficiency and KRAS G12C mutation: a case study and treatment challenges

Chengwei Jin
Hong Ge
Dongsheng Hou
Jing Li
Mingming Tan

doi 10.3389/fonc.2024.1515240

959 views

Share on

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology
- Cancer Immunity and Immunotherapy
- 3.5 impact factor
- 6.2 citescore

Impact

14kTopic views
10kArticle views
3,286Article downloads

View impact

Articles

B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer

Complete remission of a high-risk, locally advanced cervical cancer with para-aortic lymph node metastases treated with first-line tislelizumab plus bevacizumab combined with chemotherapy followed by radiotherapy with maintenance therapy: a case report

The administration sequences of immune checkpoint inhibitors and chemotherapy cause discrete efficacy when treating non-small cell lung cancer: a retrospective study

Comparison of immunotherapy based total neoadjuvant therapy or standard neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional retrospective study

Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis

Neoadjuvant immunotherapy for NSCLC: superior combination strategies, optimal treatment cycles, and predictive indicators from a Bayesian meta-analysis

Efficacy and safety of Geptanolimab in previously treated PD-L1-Positive recurrent or metastatic cervical cancer: a multi-center openlabel, single-arm, phase Ⅱ study

Case Report: Metastatic succinate dehydrogenase–deficient gastrointestinal stromal tumor treated with chemotherapy and immune checkpoint inhibitor

Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer

The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

Combination chemotherapy with sintilimab for treatment of a male patient with primary pulmonary choriocarcinoma: a case report and literature review

Case report: Aggressive NSCLC with partial BRG-1 deficiency and KRAS G12C mutation: a case study and treatment challenges

Frontiers in Immunology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Oncology

Cancer Immunity and Immunotherapy